CO41 Long-Term Clinical Outcomes in People with Heart Failure with Preserved Ejection Fraction (HFpEF) Treated with Standard Care
To model clinical outcomes in a cohort of patients with symptomatic HFpEF over a lifetime horizon. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Sun, V. Dayer, R.N. Hansen, Y. Du, T. Williamson, S.X. Kong, P. Mernagh, R. Singh, K. Folkerts, S. Allen, S. Sullivan Source Type: research
CO42 4P Care and Adjusting Therapy for Hypothyroidism – A Potential to Reduce Costs of Healthcare and Loss of Productivity
Hypothyroidism affects 25 million people in the US, causing health complications and increased healthcare utilization for many patients despite well-established hormone replacement therapy. A significant effort goes into understanding how personalized care for chronic patients can improve health outcomes, and reduce associated healthcare costs. We focused on two complications frequently affecting hypothyroid patients: (I) fatigue – known to increase workplace absenteeism and the economic burden on healthcare payers; (II) excessive body weight – known to increase the risk of health complications and total cost of care. ...
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: V. H ögqvist Tabor, M. Tarasova, G. Cohen-Skalli, F. Dubois, B. Curran, B. Candea, M. Murphy Source Type: research
CO43 Projecting Cardiovascular Benefits Associated With Tirzepatide's Effects on Cardiovascular Risk Factors in Patients With Type 2 Diabetes in France: A Simulation Study
Tirzepatide is a GIP/GLP-1 receptor agonist approved for the treatment of type 2 diabetes (T2D) that is associated with superior reductions in glycated hemoglobin and body weight versus a range of existing therapies. The present analysis aimed to model the benefits on cardiovascular (CV) outcomes associated with tirzepatide from demonstrated improvements in CV risk factors (RF) versus no change in RF, with a focus on major adverse cardiovascular events (MACE) as the primary outcome. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: B. Osumili, N. Debackere, L. Ludwig, H. Sharland Source Type: research
CO45 A Systematic Review of Quality of Life and Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) is a common condition associated with functional impairment and loss of productivity. Management and the patient perspective may be better understood when considering the quality of life patients experience. The purpose of this study was to perform a systematic review involving GERD and quality of life parameters. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Goldsmith, S. Das, J. Hoffsten Source Type: research
CO48 A Systematic Review of Effectiveness and Safety of Acupuncture on Suicidal Behavior
In situations where death by suicide is a major global issue and effective prevention and management approaches are lacking, acupuncture improves some risk factors for suicide, including depression, substance abuse, and post-traumatic stress disorder and has been used for a long time in clinical settings. This review aimed to investigate the effectiveness and safety of acupuncture for suicidal behaviors. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C.Y. Kwon Source Type: research
CO49 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Ixekizumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis
Bimekizumab, a monoclonal IgG1 antibody, selectively inhibits IL-17F in addition to IL-17A. A previously presented network meta-analysis established similar relative efficacy for ASAS outcomes at Week (Wk)16 with subcutaneous bimekizumab 160mg every four weeks (Q4W) versus subcutaneous ixekizumab 80mg Q4W, an IL-17A-only inhibitor, in patients with radiographic axSpA (r-axSpA; i.e. ankylosing spondylitis). This matching-adjusted indirect comparison (MAIC) assessed the relative efficacy of bimekizumab versus ixekizumab at Wk52. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: H. Thom, K. Gaffney, M. M ørup, V. Taieb, D. Willems, W.P. Maksymowych Source Type: research
CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea
This study aimed to assess the characteristics and risk of recurrence for patients with osteoporotic fracture (OF) in South Korea. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Kim, H. Han, D. Pyun, E. Wang, M.J. Kim, H.S. Suh Source Type: research
CO51 Safety Profile of Approved Alzheimer's Medication By USFDA
ADRD will affect 6.7 million Americans aged 65+ in 2023, expected to double by 2050. Pharmacological management includes two symptomatic approaches: inhibition of acetylcholinesterase (donepezil, galantamine, rivastigmine) and N-methyl-D-aspartate receptors. Recommended treatments are AChEIs for mild-moderate AD. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Almutairi, V. Sanogo, K. Diaby Source Type: research
CO52 Comparative Analysis of Tabelecleucel Versus Standard of Care in Patients with EBV+ PTLD Following Hematopoietic Cell Transplant (HCT) or Solid Organ Transplant (SOT)
This study assessed treatment effect of tabelecleucel in the single-arm phase 3 ALLELE study (NCT03394365) versus a standard-of-care group drawn from a multinational, multicenter retrospective chart review study (ATA129-RS002) of patients with EBV+ PTLD following HCT or SOT. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M.A. Brookhart, A. Barlev, M. Mohty, H. Zimmermann, N. Guzman-Becerra, A. Mehta, B. Macabeo, S. Suissa Source Type: research
CO53 A Review of Treatment Effect Modifiers and/or Prognostic Factors Included in Unanchored Indirect Treatment Comparisons (ITCs) Involving Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Unanchored ITCs should adjust for effect modifiers and prognostic variables when comparing treatment arms between single-arm trials or observational studies that do not share a common comparator. To inform future analyses, we performed a literature review to identify effect modifiers and/or prognostic factors included in unanchored ITCs for TCE RRMM. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: K. Towle, C. Caisip, K. Karampampa, S. Cope, D. Dhanda Source Type: research
CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
Use of valid SEs enables assessment of long-term efficacy of treatments in absence of OS from the RCTs. We evaluated RFS as an SE for OS in resected stage II/III melanoma using trial-level data. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Leung, J. Kirkwood, S. Srinivasan, M. Dyer, A. Qian, M.M. Pourrahmat, E. Kasireddy, J.R. May, A. Moshyk, M. Kurt Source Type: research
CO56 Radiographic Progression Free Survival as a Surrogate Endpoint for Overall Survival Among Men With Metastatic Castration-Resistant Prostate Cancer
Development of targeted and novel therapies in oncology necessitates identification of surrogate endpoints. Determining patient benefit in the absence of death or other complications is vital in drug development and patient care. Radiographic progression-free survival (rPFS) is used as a co-primary endpoint among men with metastatic castration-resistant prostate cancer (mCRPC) in randomized clinical trials (RCT). Overall survival (OS) is accepted as the gold standard clinical endpoint, but it requires long follow-up. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: V.K. Maheshwari, A. Biswas, A. Chakravarty, J. Vanderpuye-Orgle, P. Pandey, P. Kondaparthi Source Type: research
CO57 A New Approach in Network Meta-Analysis Using Blended Survival Curves to Extrapolate Long-Term Survival from Immature Data
In the absence of head-to-head trials, synthesis of clinical effectiveness plays an essential role in health economic evaluations. Interim analyses of trials with limited follow-up are increasingly used to inform regulatory approval so that the evaluations require extrapolating survival curves beyond the immature data. While traditional methods of network meta-analysis (NMA) assume constant treatment effect over whole time horizon, guidance from various health authorities have indicated implausibility of the assumption and suggested incorporation of external data further. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: Z. Che, N. Green, G. Baio Source Type: research
CO58 Patient Characteristics and Treatment Patterns in Patients with Mantle Cell Lymphoma in Spain: A Real-World, Cross-Sectional Study
Describing the profile and management of patients with Mantle Cell Lymphoma (MCL) in Spain. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Esteban-Burgos, A. Molero, R. Varea, S. D íaz Cerezo, N. Milloy, A. Kiran Source Type: research
CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)
Due to lack of head-to-head randomized clinical trials comparing NIVO+RELA vs BRAF/MEK inhibitors for first-line treatment of BRAF-mutant aMel, we evaluated the efficacy of NIVO+RELA vs dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), and vemurafenib+cobimetinib (VEM+COBI) via MAICs. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: F. Ejzykowicz, J. Palaia, D. Steffen, M. Mattera, J. Zhou, B. Ratto, A. Moshyk, D. Patel, A. Salvatore, V. Garcia-Horton Source Type: research
